EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective

Steven Chun-Min Shih iD, Sita Bhella

Current Oncology · 2024

DOI: 10.3390/curroncol31070292 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2024. Verfasst von Steven Chun-Min Shih und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) is an incurable plasma cell malignancy. In the context of the current standard of care therapies in Canada, outcomes among patients with relapsed/refractory multiple myeloma (RRMM), particularly those with triple-class (or more) refractory disease remain poor. Immunotherapies have significantly changed the treatment landscape of MM. Since 2021, two BCMA-targeting CAR T-cell therapy products have been approved for RRMM—namely Idecabtagene vicleucel (Ide-cel) (ABECMA®) and Ciltacabtagene autoleucel (Cilta-cel) (CARVYKTI®), both of which are available in the US and Europe. Although they have shown unprecedented efficacy in RRMM, their clinical and logistical limitations must be acknowledged. MM CAR T-cell therapy is likely to be approved in Canada soon. Therefore, it is timely that we review the latest evidence for commercially available CAR T-cell therapy in multiple myeloma, with a focus on its relevance and impact in the Canadian setting. There will be challenges to access and strategies must be in place to ensure equitable care for all Canadians with MM. Alongside haematologists working in the immune effector cell therapy programs, providers in the community will also play a role in the ongoing monitoring and management of long-term side effects including opportunistic infections and late neurotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveReceptors, Chimeric AntigenCanadaHumansTreatment OutcomeHealth Services AccessibilityDrug CostsDrug IndustryForecasting

Stichwörter der Autor:innen

CAR Timmunotherapymyeloma

Substanzen

Receptors, Chimeric Antigenidecabtagene vicleucel

Autor:innen und Institutionen

  • Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.

ORCID-Profile: Steven Chun-Min Shih

Zitieren

APA

Shih, S. C., & Bhella, S. (2024). Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective. Current Oncology. https://doi.org/10.3390/curroncol31070292

Vancouver

Shih SC, Bhella S. Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective. Current Oncology. 2024. doi:10.3390/curroncol31070292

BibTeX
@article{Shih2024,
  author = {Shih, Steven Chun-Min and Bhella, Sita},
  title = {Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31070292}
}
Kostenlos starten →